Previous 10 | Next 10 |
2023-10-11 09:55:22 ET DENVER, Colo., Oct. 11, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Tempest Therapeutics (NASDAQ: TPST), Plug Power (NASDAQ: PLUG), Matinas BioPharma (AMEX: MTNB), Gaucho Group ...
BRISBANE, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today announced that its Board of Directors (the “Board...
New data package reveals improvements in multiple categories for TPST-1120 combined with atezolizumab + bevacizumab versus standard of care atezolizumab + bevacizumab in a global Phase 1b/2 study 30% confirmed ORR achieved in TPST-1120 arm compared to 13.3% for atezolizumab + bevac...
2023-10-11 07:47:29 ET DENVER, Colo., Oct 11, 2023 ( www.247marketnews.com )- Tempest Therapeutics, Inc. (NASDAQ: TPST) stated, after yesterday’s market close, that it plans to report new and updated data from the global randomized Phase 1b/2 combination study of TPST-1120 with a...
BRISBANE, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the company plans to report new and updated data...
BRISBANE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, announced today that executive vice president and chief medical...
BRISBANE, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, announced today that Sam Whiting, M.D., Ph.D., chief medical of...
2023-08-11 04:27:51 ET Tempest Therapeutics press release ( NASDAQ: TPST ): Q2 GAAP EPS of -$0.54 misses by $0.06 . Tempest ended the second quarter with $17.6 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022. For further detai...
BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class i therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, ...
In vitro and in vivo data show significant increased potency by blocking prostaglandin PGE2 signaling through both EP2 and EP4 receptors compared to celecoxib or single EP4 antagonists TPST-1495 anti-tumor response shown to be both immune dependent and immune independent Preclinic...
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Tempest Therapeutics Inc. Website:
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves ...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global ran...